SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened volatility and intense debate as investors weigh the company's aggressive Bitcoin treasury strategy against concerns regarding shareholder dilution and broader market instability. The community remains deeply divided, with bulls pointing to the potential for significant long-term leverage, while bears and skeptics express concerns over high debt levels and the stock's recent performance relative to Bitcoin.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing significant volatility driven by high short interest and retail sentiment surrounding a potential short squeeze, while investors debate the company's long-term valuation amid broader geopolitical concerns. Community discussion is focused on the tension between strong enterprise deal pipelines and technical selling pressure, with many traders closely monitoring support levels for a potential reversal.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is currently trending as investors anticipate pivotal late-breaking phase 3 data for its lead asset, Sonelokimab, at the American Academy of Dermatology annual meeting. The community is focused on the potential for Sonelokimab to be validated as a "best-in-class" therapy for hidradenitis suppurativa, with active discussions centering on the significance of week-40 long-term durability results and the ongoing potential for a lucrative strategic acquisition by major pharmaceutical players.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors look toward the upcoming 10-K filing and earnings report, with the community closely tracking the company's debt reduction efforts and the performance of key holdings like Applied Digital and BW. Bullish sentiment remains high despite short-interest pressure, as retail investors anticipate a potential valuation re-rating driven by balance sheet improvements and strong asset performance.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is experiencing heightened volatility and intense community debate as investors weigh the company's multi-year share price decline against potential turnaround catalysts like the upcoming World Cup. While some traders are bracing for further downside amid tariff concerns and shifting consumer demand, others are actively accumulating shares at multi-year lows, betting that long-term brand resiliency and insider buying signal an impending recovery.

Applied Digital Corporation

Applied Digital is experiencing significant volatility as investors weigh the stock's long-term potential in AI infrastructure against broader market pressures, including geopolitical instability and anticipation ahead of upcoming earnings. While some community members are expressing frustration over the recent sharp decline and delayed updates, others are viewing the current price levels as a strategic buying opportunity for long-term positions.

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals is trending after receiving FDA approval for EMPAVELI to treat rare kidney diseases, a long-awaited catalyst that investors hope will diversify revenue and bolster the company's valuation. Community discussion is heavily focused on the potential for this approval to spark a long-term turnaround, with many traders debating the stock's M&A prospects and its ability to finally sustain growth against competitive market pressures.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as investors react to the company's reported acquisition of Blue Bottle Coffee by its majority shareholder, Centurium Capital, and a significant 5% stake accumulation by First Beijing Investment. The community is actively debating whether this move signals a broader international expansion strategy and potential future relisting on major U.S. exchanges, while many users are focused on identifying the long-term value amid ongoing volatility and concerns regarding majority-owner control.

Texxon Holding Ltd. provides supply chain management services in East China. Its services include the sale of plastic, chemical raw materials, and other plastic raw materials. Its products are used in fabrics, coastings, resins, beverage packing, other downstream products, pipelines and pipes used in infrastructure, daily or food grade packing and agriculture membranes. The company was founded on January 20, 2022 and is headquartered in Shanghai, China.

Texxon Holding Ltd

Texxon Holding is capturing significant attention as traders monitor its micro-float setup and history of extreme volatility for potential short squeeze opportunities. While some participants are actively scalp-trading the stock's parabolic intraday moves, others remain skeptical, citing concerns about its history as a Chinese-listed microcap prone to rapid price reversals and dilution.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a focal point of intense community debate, driven by a mix of long-term sentiment among holders banking on institutional tokenization and a vocal group of traders focused on recent volatility and all-time low price points. Discussions are currently centered on the impact of a newly constituted Board of Directors and the project's pivot toward U.S. operations, with the community split between those accumulating 

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of "Hold" from Brokerages

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) has been assigned an average recommendation of "Hold" from the six ratings firms that are currently covering the company, Marketbeat.com...

Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen upgraded Milestone Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday...

Milestone Pharmaceuticals (MIST) Projected to Post Earnings on Tuesday

Milestone Pharmaceuticals (NASDAQ:MIST) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 31. (View Earnings Report at...

Equities Analysts Issue Forecasts for MIST FY2028 Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Equities researchers at HC Wainwright lowered their FY2028 earnings per share estimates for shares of Milestone Pharmaceuticals in a research report issued on Friday, March 20th. HC Wainwright analyst B. Folkes now forecasts that the compa...

Milestone Pharmaceuticals (NASDAQ:MIST) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.02. The firm had revenue of $1.44 million during the quarter, compared to the...

Milestone Pharmaceuticals Q4 Earnings Call Highlights

Milestone Pharmaceuticals (NASDAQ:MIST) executives highlighted the company's transition to commercialization during a year-end 2025 update call, following the U.S. Food and Drug Administration's...

Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Earnings report for Milestone Pharmaceuticals Inc. (MIST) expected on March 19. Analysts predict 16 cents per share on $1.20M revenue.read more...

Boxer Capital Management LLC Invests $1.33 Million in Milestone Pharmaceuticals Inc. $MIST

Boxer Capital Management LLC purchased a new stake in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) during the third quarter, according to its most recent Form 13F filing with...

Milestone Pharmaceuticals Inc. $MIST Shares Purchased by Propel Bio Management LLC

Propel Bio Management LLC boosted its holdings in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) by 186.1% during the 3rd quarter, according to its most recent filing with the...

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Rating of "Hold" from Brokerages

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) have received a consensus recommendation of "Hold" from the six analysts that are presently covering the company, MarketBeat...

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.

Milestone Pharmaceuticals Inc

iShares Dynamic Equity Active ETF ($BDYN)

Grayscale Bitcoin Trust ETF ($GBTC)

Destiny Tech100 Inc ($DXYZ)

Global X Defense Tech ETF ($SHLD)

The Modern Portfolio Builder. This award honors the fund that makes long-term investing easier, cheaper, or more effective for people who want to "set it and forget it."

MIST
Milestone Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MIST News

MISTMilestone Pharmaceuticals Inc